J. Emery

发表

Therapeutic modulation of transcription factor activity.

M. Jaye, E. Ohlstein, J. Emery, 2001, Trends in pharmacological sciences.

Identification of Benzimidazole Diamides as Selective Inhibitors of the Nucleotide-Binding Oligomerization Domain 2 (NOD2) Signaling Pathway

J. Bertin, V. Kasparcova, Jong W. Yu, 2013, PloS one.

Identification of Selective Small Molecule Inhibitors of the Nucleotide-Binding Oligomerization Domain 1 (NOD1) Signaling Pathway

J. Bertin, V. Kasparcova, Zining Wu, 2014, PloS one.

Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages.

R. Kirkpatrick, J. Emery, P. Lysko, 1997, Experimental cell research.

Human cartilage glycoprotein 39 (HC gp-39) mRNA expression in adult and fetal chondrocytes, osteoblasts and osteocytes by in-situ hybridization.

R. Kirkpatrick, J. Emery, R. Dodds, 2000, Osteoarthritis and cartilage.

Targeting IRAK4 for Degradation with PROTACs.

J. Harling, J. Emery, X. Lewell, 2019, ACS medicinal chemistry letters.

MALT1 Protease Activity Is Required for Innate and Adaptive Immune Responses

J. Bertin, M. Ringenberg, K. Foley, 2015, PloS one.

TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis.

J. Foley, N. Laping, J. Cottom, 2017, Blood advances.

Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents

L. Suva, P. W. Fisher, M. Nuttall, 2001, Cancer Chemotherapy and Pharmacology.

Characterization of a human cDNA encoding a widely expressed and highly conserved cysteine-rich protein with an unusual zinc-finger motif

S. A. Liebhaber, J. G. Emery, M. Urbanek, 1990, Nucleic Acids Res..

Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells.

P. Young, J. Emery, J. Terrett, 1997, Gene.

Herpesvirus Entry Mediator Ligand (HVEM-L), a Novel Ligand for HVEM/TR2, Stimulates Proliferation of T Cells and Inhibits HT29 Cell Growth*

P. Young, P. Mcdonnell, C. Silverman, 1998, The Journal of Biological Chemistry.

Two distinct species of human growth hormone-variant mRNA in the human placenta predict the expression of novel growth hormone proteins.

S. Liebhaber, J. Ray, N. Cooke, 1988, The Journal of biological chemistry.

Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL*

John C. Lee, P. Young, P. Mcdonnell, 1998, The Journal of Biological Chemistry.

Intracellular signaling pathways as a target for the treatment of rheumatoid arthritis.

S. Kumar, S. Blake, J. Emery, 2001, Current opinion in pharmacology.

Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors.

R. Keenan, M. Cheung, A. Oliff, 2021, ACS medicinal chemistry letters.

Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines.

Douglas W. Thomson, G. Drewes, M. Bantscheff, 2017, Journal of medicinal chemistry.

Emerging therapies for osteoporosis

Susheel Kumar, J. Emery, M. Gowen, 2000, Best practice & research. Clinical rheumatology.

Identification and cloning of a human urea transporter HUT11, which is downregulated during adipogenesis of explant cultures of human bone

J. Mooney, L. Suva, M. Nuttall, 2000, Journal of cellular biochemistry.